Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01990846 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, and PK of Escalating Doses of Flufirvitide-3 Dry Powder for Inhalation in Healthy Subjects
A Phase 1 study of Influenza, sponsored by Autoimmune Technologies.
- Completed
- Registry status
- Phase 1
- Development phase
- 68
- Enrollment target
- 1
- Study location
NCT01990846 is a Phase 1 study of Influenza that has completed, run by Autoimmune Technologies. The registered enrollment target is 68 participants, below the 36,804-participant average among 156 other Influenza trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01990846, a Phase 1 study of Influenza, has completed, sponsored by Autoimmune Technologies.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 68 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate the safety, tolerability and pharmacokinetics (PK) of single,and repeat escalating doses of FF-3 dry powder administered via inhalation in healthy adult subjects
Conditions Studied
Interventions
- DRUG Flufirvitide 3
- DRUG Placebo for Flufirvitide-3
Study Locations (1)
South Carolina
- Spartanburg Medical Research - Spartanburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2014-03 |
| Est. Completion | 2015-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01990846
The ClinicalTrials.gov registry entry for NCT01990846 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 36,804-participant average among 156 other Influenza trials with a reported enrollment target (100% lower). The listed sponsor is Autoimmune Technologies, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Influenza appearing as the primary indexed condition, and to 2 interventions - of which Flufirvitide 3 is the first listed.
NCT01990846 reports 1 study location spanning 1 distinct geographic area - top geographies include South Carolina.
Frequently Asked Questions
What is clinical trial NCT01990846 about?
NCT01990846 is a clinical study titled "Safety, Tolerability, and PK of Escalating Doses of Flufirvitide-3 Dry Powder for Inhalation in Healthy Subjects". To evaluate the safety, tolerability and pharmacokinetics (PK) of single,and repeat escalating doses of FF-3 dry powder administered via inhalation in healthy adult subjects
What is the current status of trial NCT01990846?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 68 participants. The study started on 2014-03. Estimated completion is 2015-02.
What conditions does trial NCT01990846 study?
This clinical trial studies the following conditions: Influenza.
What interventions are being tested in trial NCT01990846?
The interventions under investigation include: Flufirvitide 3 (DRUG), Placebo for Flufirvitide-3 (DRUG).
Who is sponsoring clinical trial NCT01990846?
This trial is sponsored by Autoimmune Technologies, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01990846 being conducted?
This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Influenza
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
pH1N1 Blinded Challenge Study
RECRUITING · Phase 1
-
A/Texas Flu Challenge
RECRUITING · Phase 1
-
First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics
RECRUITING · Phase 1
-
Influenza Human Challenge Model
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults
ACTIVE NOT RECRUITING · Phase 1
-
Pilot Influenza Challenge Study
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.